Search Results - "Esteves, Brooke"

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial by MOTZER, Robert J, NOSOV, Dmitry, KOGAN, Mikhail, ALEKSEEV, Boris Y, STERNBERG, Cora N, SZCZYLIK, Cezary, CELLA, David, IVANESCU, Cristina, KRIVOSHIK, Andrew, STRAHS, Andrew, ESTEVES, Brooke, BERKENBLIT, Anna, EISEN, Timothy, HUTSON, Thomas E, BONDARENKO, Igor, LESOVOY, Vladimir, LIPATOV, Oleg, TOMCZAK, Piotr, LYULKO, Oleksiy, ALYASOVA, Anna, HARZA, Mihai

“…Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial…”
Get full text

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma by NOSOV, Dmitry A, ESTEVES, Brooke, LIPATOV, Oleg N, LYULKO, Alexei A, ANISCHENKO, A. A, CHACKO, Raju T, DOVAL, Dinesh C, STRAHS, Andrew, SLICHENMYER, William J, BHARGAVA, Pankaj

“…The antitumor activity and safety of tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, was…”
Get full text

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study by Matulonis, Ursula A, Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A, Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G, Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L

“…Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab…”
Get full text

MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression by Moore, Kathleen N., Van Gorp, Toon, Wang, Jiuzhou, Esteves, Brooke, Zweidler-McKay, Patrick A

“…Abstract only TPS6103 Background: Elevated FRα expression is a characteristic of several solid tumors, including epithelial ovarian cancer (EOC), thereby…”
Get full text

Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite by Tu, Ya‐Ping, Hanze, Eva, Zhu, Fengying, Lagraauw, H. Maxime, Sloss, Callum M., Method, Michael, Esteves, Brooke, Westin, Eric H., Berkenblit, Anna

“…Aims Mirvetuximab soravtansine is a first‐in‐class antibody–drug conjugate recently approved for the treatment of folate receptor‐α positive ovarian cancer…”
Get full text

Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study (002) by Coleman, Robert, Oaknin, Ana, Pignata, Sandro, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason, Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth, Esteves, Brooke, Method, Michael, Lorusso, Domenica, Matulonis, Ursula

Get full text

Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study by Matulonis, Ursula A., Oaknin, Ana, Pignata, Sandro, denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A., Romeo, Marga, Harter, Philipp, Murphy, Conleth G., Wang, Jiuzhou, Method, Michael W., Esteves, Brooke, Coleman, Robert L., Lorusso, Domenica

“…5512 Background: SORAYA is a global single arm phase 3 study evaluating MIRV in patients (pts) with FRα high platinum-resistant ovarian cancer (PROC). MIRV is…”
Get full text

Reply to Z.R. McCaw et al by Matulonis, Ursula A., Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A., Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G., Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L.

Get full text

MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297) by Moore, Kathleen, Konecny, Gottfried, Martin, Lainie, Floquet, Anne, O’Malley, David, Colombo, Nicoletta, Mantia-Smaldone, Gina, Banerjee, Susana, Gilbert, Lucy, de Gregorio, Nikolaus, Tromp, Jacqueline, Wang, Jiuzhou, Esteves, Brooke, Method, Michael, Van Gorp, Toon

Get full text

Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4) by Matulonis, Ursula, Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Denys, Hannelore, Colombo, Nicoletta, Gorp, Toon Van, Konner, Jason, Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth, Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert

Get full text

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis by O'Malley, David M., Oaknin, Ana, Matulonis, Ursula A., Mantia-Smaldone, Gina, Lim, Peter C, Castro, Cesar Martin, Provencher, Diane M., Memarzadeh, Sanaz, Zweidler-McKay, Patrick A., Wang, Jiuzhou, Esteves, Brooke, Moore, Kathleen N., Gilbert, Lucy

“…Abstract only 5504 Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a…”
Get full text

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial by Coleman, Robert L, Lorusso, Domenica, Oaknin, Ana, Cecere, Sabrina Chiara, Denys, Hannelore, Colombo, Nicoletta, van Gorp, Toon, Konner, Jason A, Romeo Marin, Margarita, Harter, Philipp, Murphy, Conleth, Wang, Yuemei, Esteves, Brooke, Method, Michael, Matulonis, Ursula

“…The single-arm, phase II SORAYA trial (NCT04296890) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer…”
Get more information

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study by Matulonis, Ursula A., Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A., Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G., Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L.

“…(Abstracted from J Clin Oncol 2023;41(13):2436–2445 Approximately 80% of patients with ovarian cancer experience recurrence after platinum-based chemotherapy,…”
Get full text

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer by Gilbert, Lucy, Oaknin, Ana, Matulonis, Ursula A., Mantia-Smaldone, Gina, Lim, Peter C, Castro, Cesar Martin, Provencher, Diane M., Memarzadeh, Sanaz, Wang, Jiuzhou, Esteves, Brooke, Zweidler-McKay, Patrick A, Moore, Kathleen N., O'Malley, David M.

“…Abstract only 6004 Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a…”
Get full text

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial by Gumbiner, Barry, Esteves, Brooke, Dell, Vanessa, Joh, Tenshang, Garzone, Pamela D., Forgie, Alison, Udata, Chandrasekhar

“…Purpose This first-in-human study assessed safety, immunogenicity, pharmacokinetics, and pharmacodynamics of RN909, a monoclonal antibody antagonist of the…”
Get full text

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors by ESKENS, Ferry A. L. M, DE JONGE, Maja J. A, VERWEIJ, Jaap, BHARGAVA, Pankaj, ISOE, Toshiyuki, COTREAU, Monette M, ESTEVES, Brooke, HAYASHI, Kunihiko, BURGER, Herman, THOMEER, Maarten, VAN DOORN, Leni

“…To assess the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective…”
Get full text

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study by O'Malley, David M., Matulonis, Ursula A., Birrer, Michael J., Castro, Cesar Martin, Vergote, Ignace, Martin, Lainie P., Mantia-Smaldone, Gina, Gilbert, Lucy, González-Martín, Antonio, Bratos, Raquel, Esteves, Brooke, Malek, Karim S., Moore, Kathleen N.

“…Abstract only 5520 Background: Mirvetuximab soravtansine is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent…”
Get full text

Reply to Z.R. McCaw et al by Matulonis, Ursula A, Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A, Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G, Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L

Get full text

Tivozanib in patients treatment-naive for metastatic renal cell carcinoma: A subset analysis of the phase III TIVO-1 study by Sternberg, Cora N., Eisen, Tim, Tomczak, Piotr, Strahs, Andrew Louis, Esteves, Brooke, Berkenblit, Anna, Motzer, Robert John

“…Abstract only 4513 Background: Tivozanib (T) is a potent, selective inhibitor of all three VEGF receptors with a long half-life of 4.5–5.1 days. Superior…”
Get full text

Rates of dose adjustment in patients treated with tivozanib versus sorafenib in the phase III TIVO-1 study by Hutson, Thomas E., Nosov, Dmitry, Harza, Mihai, Esteves, Brooke, Strahs, Andrew Louis, Berkenblit, Anna, Motzer, Robert John

“…Abstract only 4564 Background: Tivozanib hydrochloride (tivozanib) is a potent, selective, tyrosine kinase inhibitor of all three vascular endothelial growth…”
Get full text